In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Amy Bucher, chief behavioural officer at Lirio, a ...

Months of uncertainty have come to a close. The BIOSECURE Act, now part of the National Defense Authorization Act (NDAA), will put in motion US government-wide restrictions on ‘biotechnology companies ...

Q4 2025 showcased the industry’s pivot toward precise biology, localised delivery, and earlier intervention – with multiple ...

Distilling that complexity into a handful of trends has been no small task. What follows is not a definitive forecast, but ...

The clinical research environment has undergone considerable transformation over the past decade. Protocols are more complex, product pipelines increasingly target smaller and more distributed patient ...

Dermot Kenny, who leads STEM and Research Partnership within Inizio Advisory, shares his journey from bench scientist to CEO, ...

The FDA has lost no time in approving the first drug under its recently launched Commissioner's National Priority Voucher (CNPV) programme, clearing an antibiotic manufactured in the US. The fast ...

GSK has escalated a dispute over rights to its cancer immunotherapy Jemperli, after its subsidiary Tesaro filed a complaint against AnaptysBio in the Delaware Court of Chancery, alleging breach of ...

Otsuka has claimed FDA approval for its IgA nephropathy (IgAN) therapy Voyxact, joining an increasingly crowded market and beating rival Vera Therapeutics to the punch. Anti-APRIL antibody Voyxact ...

The Coalition for Epidemic Preparedness Innovations (CEPI), a public-private partnership, is providing up to $54.3 million in ...

Our roundup of financings in the biotech arena this week is led by a $125 million Series A for Ambros Therapeutics, a startup ...

The green light for Rybrevant Faspro – which combines amivantamab with hyaluronidase – means that the drug is the first ...